NCT05309564

Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter

Muscle Weakness Duration Post-injection of a Single Dose of Botulinum Toxin in the Masseter Muscle Bilaterally: a One-year Non-randomized Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Region Västerbotten · Other Government
• Sex: Female
• Age: 18 Years – 120 Years
• Healthy volunteers: Accepted

Summary

This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH \& Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units).

Detailed description

This study aimed to evaluate the duration of a reduced maximal voluntary bite force (MVBF) after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH \& Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units). A control group did not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the incisors and first molars. The intervention group was comprised of individuals seeking aesthetic treatment for masseter reduction (n = 20), and the control group (n = 12) comprised of volunteers.

Conditions

• Bite Force
• Botulinum Toxins, Type A

Interventions

Type	Name	Description
DRUG	Botulinum toxin type A	Single intervention

Timeline

• Start date: 2020-03-01
• Primary completion: 2022-01-10
• Completion: 2022-03-14
• First posted: 2022-04-04
• Last updated: 2023-05-03

Locations

1 site across 1 country: Sweden